M. pneumoniae Infection Linked to Guillain-Barré Syndrome

This article originally appeared here.
Share this content:
<i>M. pneumoniae</i> Infection Linked to Guillain-Barr&eacute; Syndrome
M. pneumoniae Infection Linked to Guillain-Barré Syndrome

FRIDAY, Aug. 12, 2016 (HealthDay News) -- Mycoplasma pneumoniae infection is associated with Guillain-Barré syndrome (GBS), according to a study published online Aug. 4 in the Annals of Neurology.

Patrick M. Meyer Sauteur, M.D., from the University Medical Center in Rotterdam, Netherlands, and colleagues examined the role of M. pneumoniae in GBS in a case-control study involving 189 adults and 24 children with GBS. Cases were compared to control cohorts for analysis of serum antibodies against M. pneumoniae (479 controls) and galactocerebroside (GalC; 198 controls).

The researchers found that 3 and 0 percent of adult GBS patients and healthy controls (P = 0.16) and 21 and 7 percent of children (P = 0.03), respectively, had anti-M. pneumoniae immunoglobulin M (IgM) antibodies. Four percent of adults and 25 percent of children with GBS had anti-GalC antibodies (P = 0.001). Patients who were positive for anti-GalC had more frequent preceding respiratory symptoms, cranial nerve involvement, and a better outcome. There was a correlation for anti-GalC antibodies with anti-M. pneumoniae antibodies (P < 0.001), and these cross-reacted with different strains of M. pneumoniae. Anti-GalC IgM antibodies were found in GBS patients with M. pneumoniae infection and in patients without neurological disease; anti-GalC IgG antibodies were only found in patients with GBS.

"M. pneumonia infection is associated with GBS, more frequently in children than adults, and elicits anti-GalC antibodies, of which specifically anti-GalC IgG may contribute to the pathogenesis of GBS," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »